Search Results

2022 08:00 AM Eastern Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio

👉 Ambition is the default setting of biotech. Platforms expand. Indications multiply. without compromising strategic control and biotech fundraising credibility? into sustainable progress and stronger biotech fundraising credibility. Why Ambition Naturally Expands in Biotech Companies 👉 Ambition in biotech is data-driven. In biotech, disciplined decisions today build strategic focus, execution clarity, and stronger biotech

👉 In early-stage biotech, activity often feels like strategy. At the same time, the team is preparing for biotech fundraising. in biotech is not complexity. In early-stage biotech, resources are finite. Capital is limited. How Strategic Overload Weakens Biotech Fundraising Signal 👉 Biotech fundraising is not only an evaluation

👉 Most biotech founders  do not realize they are in trouble when the money runs out. Biotech founders rarely notice this moment because nothing visibly breaks. Why biotech founders do not see the warning signs early enough 👉 The core problem is not that biotech In early-stage biotech, progress is measured through science. Experiments advance. Data improves. This is where many biotech founders lose visibility.

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. In early-stage biotech, fundraising rarely feels like a strategic threat. Fundraising rarely breaks biotech startups overnight. This is where one of the most common biotech startup fundraising mistakes takes root.   👉 Strong biotech startups do not fail at this stage because they stopped working hard.

Most biotech founders assume that failure comes from making the wrong call. A flawed experiment. A missed partnership. 👉 Biotech startup failure is usually imagined as a moment where something clearly In reality, many biotech startups drift into trouble without ever making a single decision that looks Why This Type of Biotech Startup Failure Is Hard to Detect 👉 What makes this form of biotech startup This is where biotech startup failure becomes operationally real .

It is a biotech positioning problem. The Symptoms of Unclear Biotech Positioning 👉 Most biotech founders feel that something is wrong in How Clear Biotech Positioning Changes External Conversations 👉 When biotech positioning is clear, external What Biotech Positioning Strategy Really Means 👉 Many biotech founders misunderstand positioning because Clear biotech positioning creates internal discipline.

👉 In early-stage biotech , uncertainty is not an exception. It is the environment. Early-stage biotech hiring is not about perfect resumes. Why Skill-Based Hiring Breaks Down in Early-Stage Biotech Most early-stage biotech teams hire with good Early-stage biotech is none of those things. 👉 In early-stage biotech hiring, skills are selected based In early-stage biotech hiring, these moments arrive quietly.

👉 Biotech startups rarely fail all at once. This is one of the earliest reasons why biotech startups fail . This is a central reason why biotech startups fail . Order does not emerge naturally in biotech. Strategic Takeaway - Why biotech startups fail Biotech startups rarely fail because of a single mistake

Biotech fundraising has undergone a subtle yet significant shift. Clear intellectual property builds confidence on both sides of the biotech fundraising table Why biotech Biotech fundraising rarely fails in the diligence phase itself. In modern biotech fundraising, intellectual property functions as a shortcut. In biotech fundraising, coherence builds trust.

But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn Operating cadence is the quiet force behind biotech momentum, the rhythm that turns intention into real The Pattern: Your “Accidental Cadence” 👉 Every biotech has a cadence. Timeline slips are absorbed as “part of biology” rather than examined as managerial signals. Strategic Takeaway Your biotech is already running on an operating cadence.

The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where The Pattern: Scientific Isolation Scientific Isolation  = when a biotech’s internal activity becomes Alignment, structure, traction, visibility: these are the forces that pull a biotech out of scientific Most early biotechs think their problem is a lack of data. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

For JB, that moment was a cold email from a biologist he’d never met, asking if he could synthesize a ask pulled a young chemist out of the fume hood and into the messy, electrifying world of live-cell biology Designing Reliable GPCR Imaging Tools for Real Biological Systems Success brought new challenges. Chemical probes may be elegant, but biology isn’t. Tissue is messy. David brought deep experience in islet biology, calcium imaging, and tissue physiology.

Most biotech pitches don’t fail because the science is weak. A clear biotech pitch answers three key questions immediately. Strong biotech pitches don’t just inform, they align. How to Fix the Gaps 👉 Fixing your biotech pitch doesn’t require a rebrand. A strong biotech pitch isn’t about saying more.

Every biotech founder fears the day the cash runs out. You track the burn rate. Example: You validate a biomarker for a broad indication. Most biotech founders don’t suffer from having the wrong people. A soft skill. ✅ But in biotech, alignment is a multiplier. It’s how biotech companies move from drift to direction.

It’s a pattern we see far too often in early-stage biotech operations and startups. The 3 Golden Rules of Scientific Thinking — and Why They Break Down in Biotech Operations Leadership   In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay Scientific thinking will always be your strength, but it must be reshaped to serve your new role. 👉 As a biotech Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical companies #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

July 2022 "G.CLIPS biotech is 2 years old today🎂. Looking forward for more 🎊 #team #grateful #biotech #work #birthdaycelebration" Read more at the source

The latest on how AI is being used to unlock elusive GPCR targets, financial results from Neurocrine Biosciences GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner, Yamina's Corner, biotech development, pharmaceutical, scientific career Hashtags: #DrGPCR #GPCR #DrugDiscovery #Pharmacology #Biotech

structural biology, computational design, pharmacology, and translational strategy. Companies already confirmed to attend include: Abalone Bio  ·  AbbVie  ·  Biagon  ·  Biolexis Therapeutics   ·  Confo Therapeutics  ·  Eli Lilly  ·  GSK  ·  Nabla Bio  ·  Northeastern University  ·  Nxera Pharma AI & ML in GPCR Drug Discovery A dedicated focus day brings together teams from Nabla Bio, Abalone Bio Companies presenting include Skymab Biotherapeutics, Confo Therapeutics, GSK, Metaphore Biotechnologies

October 2022 "Enzymatic and cellular signalling biosensors are used to decipher the activities of complex biological systems. Biosensors for monitoring G protein-coupled receptors (GPCRs), the most drugged class of proteins in Here, we briefly summarize a subset of this field with accelerating importance: transducer biosensors

August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology in Cell Membranes and Living Cells "Conformational biosensors to monitor the activation state of G protein-coupled reported the initial characterization of a NanoBRET-based conformational histamine H3 receptor (H3R) biosensor In the current study, we have further characterized this H3R biosensor on intact cells by monitoring In addition, we have validated the H3R biosensor in membrane preparations and found that observed potency

August 2022 "Genetically encoded fluorescent biosensors allow intracellular signaling dynamics to be Many such biosensors are based on the principle of Förster resonance energy transfer (FRET), and we have recently developed a simple approach for in vivo detection of FRET-based biosensor signals using fiber By combining fiber photometry with FRET-based biosensors, we were able to track GPCR-dependent signaling This methodology would be compatible with other mammalian species and with many biosensors.

The Impact of Twist Bioscience Twist Bioscience serves life science researchers who are dedicated to Various spacers and hinges are utilized at this stage, and the biological evaluation of these compounds Seven compounds based on P1 and P3 were tested by Twist Bioscience. Commun Biol 2020 , 3 (1), 786. https://doi.org/10.1038/s42003-020-01518-8 . (3) Monk, P. Biomedicine & Pharmacotherapy 2022 , 153 , 113408. https://doi.org/10.1016/j.biopha.2022.113408 . (5

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

December 2021 Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine Food and Drug Administration in 2022 SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (

that in connection with the Collaboration and License Agreement (“License Agreement”) with Neurocrine Biosciences (“Neurocrine Biosciences”) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino the applicable waiting period under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

June 2022 Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adult (18 years of age and older) Patients with Classic CAH SAN DIEGO, June 13, 2022 -- Neurocrine Biosciences

that closed door lit the fuse for a career that would reimagine GPCR therapeutics — and lead to two biotech What followed was a scientific journey that now spans two biotech startups, and a bold reimagining of Clifford Woolf, a leader in pain biology. Launching Blue was Ajay’s first hands-on experience with biotech entrepreneurship. Lessons From the Front Lines of Biotech Ajay’s experience in both early-stage biotech and academic science